VivoSeq
Oncology

Myeloproliferative Neoplasm

3

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Myeloproliferative Neoplasm is an early-stage landscape with 3 programs across 2 companies. The most active players are AbbVie, Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Pacritinib

OrsoBio, Inc

Phase 22

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Venetoclax

AbbVie

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Active, not recruiting1 · 17%
Completed1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Recruiting·—·Phase 1·NCT05025488·10 enrolled
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Recruiting·WWake Forest University Health Sciences·N/A·NCT06480591·35 enrolled
Venetoclax and Azacitidine Combination Therapy for Patients With Accelerated or Blast Phase BCR-ABL Negative Myeloproliferative Neoplasm (VAAMP)
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05074355·40 enrolled
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Active, not recruiting·AbbVie logoAbbVie·Phase 1·NCT04041050·85 enrolled
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT07679334·20 enrolled
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Completed·OOttawa Hospital Research Institute·Phase 2·NCT04243122·44 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)